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ABSTRACT 
Background  
Control of severe, unstable asthma remains a challenge particularly in non-
atopic patients who are currently denied anti-IgE therapy which is perceived as 
ineffective.  
Objective 
Utilise a randomised, double-blind, placebo controlled study to establish proof 
of principle that omalizumab can stabilise lung function while reducing 
bronchial mucosal inflammation in non-atopic asthmatics. 
Methods 
16 symptomatic, non-atopic asthmatics were destabilised following 
randomisation (1:1) to receive omalizumab or identical placebo treatment for 20 
weeks. Lung function (FEV1), asthma-related symptoms (Juniper ACQ, ACD) 
and quality of life (Juniper mini-AQLQ) were monitored. Inflammatory cells 
were enumerated in sections of bronchial mucosal biopsies collected before and 
after 16 weeks of treatment. 
Results  
Substantial, supervised reduction of regular therapy resulted in a decline in lung 
function in the placebo treated patients which was reversed in the omalizumab 
treated patients with highly significant differences in absolute (p=0.02) and % 
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predicted FEV1 (p=0.009) with corresponding clinically, if not statistically 
significant improvements in asthma symptoms (ACQ) and quality of life (mini-
AQLQ). Omalizumab, compared with placebo therapy was also associated with 
highly significant median percentage reductions in the numbers of bronchial 
mucosal total IgE
+
 cells (p<0.001), mast cells (p<0.001) and plasma cells 
(p=0.005). IgE
+
 mast cells were also reduced but not significantly.  Mucosal B 
lymphocytes and eosinophils were not altered.  
Conclusion 
Omalizumab stabilises and improves lung function in non-atopic asthmatics, 
possibly at least partly by reducing bronchial mucosal inflammation and IgE 
expression. A policy of restricting therapy to asthmatics with the “endotype” of 
atopy as conventionally defined may exclude potential responders.  
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Clinical Implication  
Omalizumab is currently denied to asthmatics categorised as “non-atopic” by 
conventional criteria. Our data suggest that the “endotype” of non-atopy is 
inappropriate for excluding potential responders.  
 
Capsule Summary  
Treatment of severe, unstable asthma s remains a challenge. In this randomized, 
double-blinded, placebo controlled proof of concept study, we addressed the 
effects of omalizumab on lung function and bronchial mucosal inflammation in 
non-atopic asthmatics. 
 
Key words 
Asthma; omalizumab; anti-IgE; non-atopic  
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Abbreviations 
ACD Asthma Control Diary 
ACQ Asthma Control Questionnaire 
AQLQ Asthma Quality of Life Questionnaire 
CTA Clinical Trial Authorisation 
FEV1 Forced Expiratory Volume in the first second 
FITC Fluorescein isothiocyanate 
GCP Good Clinical Practice 
NICE National Institute of Health and Care Excellence 
OCT Optimal Cutting Temperature 
PBS Phosphate Buffered Saline 
PFA Paraformaldehyde 
SIQR Semi-Interquartile Range 
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INTRODUCTION 
Asthma remains a leading cause of suffering affecting about 300 million 
people worldwide
1
 and 25.7 million in the US
2
. In the UK, 10% of the 5.2 
million sufferers are estimated to retain daily symptoms and remain vulnerable 
to acute exacerbations despite the regular and efficient delivery of conventional 
anti-asthma therapy, including systemic corticosteroid
3
.  
The humanised, monoclonal IgG1 anti-IgE antibody omalizumab is the 
vanguard of what will hopefully form an arsenal of new biologicals able to 
improve the lives of severe asthma sufferers. That omalizumab therapy 
stabilises asthma control, reducing disease exacerbations, and consequently 
unplanned hospital admissions and exposure to systemic corticosteroid therapy 
in a substantial proportion of severe asthmatics is now acknowledged by 
professional and regulatory authorities worldwide, including the British 
Thoracic Society (BTS) and NICE
4
 in the UK. 
A major challenge when deploying treatment with biologicals for severe 
asthma is the possibility of mechanistic variation in the disease, requiring pre-
identification of potential responders to any specific agent. This has generated 
intense interest in identifying “phenotypes” or “endotypes” of asthma. In the 
case of omalizumab, the prima facie effect of which is to prevent, and possibly 
reverse binding of IgE to its high- and low-affinity receptors
5, 6
, the tacit 
assumption has been that it improves asthma stability fundamentally by 
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reducing or abolishing mast cell and basophil activation by cross-linking of 
surface-bound allergen-specific IgE by allergen in suitably sensitised, “atopic” 
patients. Consequently, key clinical trials investigating its efficacy, such the 
INNOVATE study
7
 have been limited to atopic asthmatics while its marketing 
authorisation restricts its use to patients with “convincing IgE-mediated 
asthma”. This phrase is not universally defined but is in practice usually equated 
with evidence of IgE sensitisation (by skin prick or in vitro testing) to one or 
more common perennial aeroallergens. Conversely, the therapy has been denied 
to at least, we estimate, 20,000 otherwise eligible non-atopic severe asthmatics 
in the UK, and many more worldwide (the prevalence of non-atopic, severe 
asthma was estimated at 50% of the total in the ENFUMOSA cross sectional 
study
8
 and 17–34% in the SARP study)9. 
 Much indirect evidence suggests that IgE may play a role in asthma 
regardless of conventional atopic status. Epidemiologically, asthma was 5 fold 
more prevalent in a cohort of non-atopic subjects with elevated total serum 
IgE
10
. We and others have shown that atopic and non-atopic asthma are virtually 
identical in terms of their bronchial mucosal cellular and molecular 
immunopathology
11-18
, evidence of local B cell switching to IgE synthesis
19, 20
, 
elevated local FcRI receptor expression21 (local IgE up regulates FcRI on 
expressing cells) and, very recently, elevated total bronchial mucosal IgE 
concentrations
22
. Furthermore, there is ample evidence that IgE directed against 
antigens other than aeroallergens, such as viral antigens
23
 and Staphylococcal 
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enterotoxins
24
 which also act as superantigens, may play a role in asthma 
pathogenesis. IgE may influence the functions of mast cells by antigen-
independent mechanisms
25, 26
. Finally, IgE may exacerbate asthmatic bronchial 
mucosal inflammation by mechanisms other than causing degranulation of mast 
cells and basophils, such as by enhancing antigen capture by antigen-presenting 
cells and activating monocyte/macrophages
27
. All of these data lend weight to 
the view that the presence or absence of atopy as operationally defined might 
not be an appropriate phenotypic or endotypic criterion for predicting 
responsiveness to omalizumab therapy. 
To address this, we hypothesised that omalizumab therapy provides 
clinical benefit in chronic, severe asthmatics designated non-atopic by 
conventional criteria. Rather than embarking on a large, lengthy and costly 
clinical trial with frequency of exacerbations as a primary outcome measure, we 
elected in the first instance to provide proof of concept in a double-blind, 
placebo controlled study that omalizumab therapy can maintain or improve lung 
function in these patients despite provocation of the disease in the shorter term 
by supervised reduction of therapy. We also sampled their bronchial mucosa at 
fibreoptic bronchoscopy before and after therapy to address the hypothesis that 
omalizumab reduces local expression of IgE as well as the numbers of B cells, 
plasma cells and mast cells.  
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STUDY DESIGN, PATIENTS AND LABORATORY METHODS 
Study protocol 
This was a randomised, placebo-controlled, double-blind, parallel-group, 
proof of concept trial of 20 weeks’ duration. Omalizumab and identical vehicle 
control manufactured to GCP standards were kindly supplied by the 
manufacturers (Novartis Pharmaceuticals). The trial was approved and 
monitored by Guy’s Research Ethics Committee (REC Ref: 09/H0804/43) and 
the Medicines and Healthcare Products Regulatory Agency (CTA No: 
14523/0219/001/0001) and registered on clinicaltrials.gov (reference 
NCT01113437). Eligible patients were moderate/severe, non-atopic asthmatics 
who provided written, informed consent recruited from the asthma clinics at 
Guy’s and St. Thomas’, the Royal Brompton and the Homerton University 
Hospitals in London, the departmental database or through advertisement.  
Asthma was defined as a history of relevant symptoms and documented (i) ≥ 
12% reversibility of FEV1 in response to inhaled bronchodilator and/or (ii) ≥ 
8% variability of the peak expiratory flow (PEF) during a 24 hour period or ≥ 
20% variability over a period of 1-2 weeks. Moderate/severe asthma was 
defined as regular (at least 3 days per week) day- and night-time symptoms in 
the 3 months prior to screening despite regular step 3-5 asthma treatment 
according to the BTS guidelines
28
. Non-atopic was defined as negative skin 
prick and/or in vitro IgE tests (Phadia ImmunoCAP® Grade 0 or ≤ 0.35 kU/L) 
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to the following local UK aeroallergens: mixed grass, mixed tree, mixed mould, 
cat, dog and house dust mite. The non-atopic status of these participants was 
further confirmed by full ISAC (Phadia) screening of their sera and bronchial 
biopsy homogenates (data presented elsewhere) 
22
. Exclusion criteria are listed 
in the online repository section.   
The phases of the study protocol are summarised in Figure I: 
Screening/baseline: After screening, during a baseline period of up to 4 
weeks patients were given and instructed to use, if necessary, a portable peak 
flow meter (Mini-Wright Standard EU Scale, SKU: 3103387, Clement Clarke 
International Limited) and blank diary forms (Juniper Asthma Control Diary
29
) 
in which they documented daily morning and evening peak expiratory flow 
(PEF) and day and night symptoms (on a 0-6 scale) until the end of the study. 
Existing anti-asthma medication was not changed at this stage but compliance 
encouraged. 
First bronchoscopy and commencement of therapy: At a second visit 
patients completed a Juniper Asthma Control Questionnaire
29
 (ACQ) and mini-
Asthma Quality of Life Questionnaire
30
 (mini-AQLQ), then underwent pre-
bronchodilator spirometry (Minispir® PC based Spirometer, Winspiro Pro 
version 4.1.5 software) prior to the obtaining of  10 technically suitable 
bronchial mucosal biopsies from the right or left second or third generation 
bronchi at fibreoptic bronchoscopy using an Olympus bronchoscope model BF 
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XT40 OES. Patients then received their first subcutaneous injection of the trial 
medication (omalizumab or identical placebo, allocated by the hospital 
pharmacy using randomisation tables with the patient and attending physician 
blinded), the dosage and frequency of which (either 2 or 4 weekly) were 
determined as in standard clinical practice based on their initial body weight and 
serum total IgE concentration as described in the Omalizumab SmPC. Where 
serum total IgE was below the lowest concentration in the SmPC dosing table 
we administered the lowest dosage in the table (75 mg every four weeks). 
Patients were observed for 2 hours afterwards. At each subsequent dosing visit, 
patients were examined clinically, encouraged to comply with their usual 
medication and their diary cards collected and renewed. 
Second bronchoscopy: Within a 2 week window between 12 and 14 
weeks after commencement of omalizumab/placebo therapy (Time a, Figure I), 
lung function was re-measured and repeat bronchial biopsies obtained as before. 
Therapy reduction phase: Patients were instructed carefully how to use a 
Turbohaler® device and asked, commencing the day following the second 
bronchoscopy, to discontinue all existing inhaled and oral anti-leukotriene or 
theophylline based anti-asthma medications and substitute them with regular 
budesonide/formoterol combination therapy (Symbicort® 100/6 Turbohaler 2 
puffs twice daily initially for 4 weeks and further reduced to 1 puff twice daily 
until the end of the trial) with additional terbutaline (Bricanyl® Turbohaler 500 
μg/puff) as required for immediate relief of symptoms. For patients taking 
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regular additional oral prednisolone, an attempt was also made progressively to 
reduce the dosage according to a predetermined regimen depending on the 
dosage at entry to the study (see Table E I in the online repository). 
Omalizumab/placebo therapy was continued for a total of 20 weeks while this 
new therapeutic regimen was pursued. 
End of the study (Time B, Figure I): At their penultimate visit, 20 weeks 
from commencement of omalizumab/placebo therapy, patients completed final 
ACQ and mini-AQLQ questionnaires then underwent repeat spirometry before 
being asked to resume their original anti-asthma therapy. A final visit was 
arranged 2 weeks later to check the patients’ wellbeing and enquire about any 
adverse reactions. 
At any time during the study, in the event of an asthma exacerbation, 
defined as a need for rescue oral corticosteroid medication for deterioration of 
symptoms and/or lung function, as agreed between the patient and the study 
physician, patients were treated with a 10 day course of prednisolone 30 mg/day 
instituted by the study physician. Such patients left the study, resumed their 
regular anti-asthma medication and were followed up as necessary.  
 
Immunofluorescence 
Bronchial biopsies were processed and analysed using double 
immunofluorescence, single immunohistochemistry and confocal microscopy 
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where appropriate according to an established protocol described in the online 
repository section of this manuscript.  
Outcome variables 
The primary outcome variables were changes in absolute and percentage 
predicted pre-bronchodilator FEV1 measured at baseline and the end of the 20 
week treatment period. Exploratory clinical outcome variables were changes in 
morning peak expiratory flow, symptom scores from asthma control diaries 
(ACD) and asthma quality of life scores (Juniper mini-AQLQ). Laboratory 
outcome variables were percentage changes in tryptase
+
 mast cells, CD138
+
 
plasma cells, CD20
+
 B lymphocytes, cells of these phenotypes co-expressing 
IgE and total IgE
+
 cells per unit area of the bronchial mucosal sections. 
Statistical analysis 
Baseline characteristics and demographic data were summarised using 
descriptive statistics. Changes in numerical variables at the beginning and end 
of the study as well as differences in changes between the omalizumab and 
placebo treated groups were analysed by non-parametric statistics (Mann-
Whitney U test). All tests were two sided and p<0.05 was accepted as 
significant. The statistical software package used was GraphPad Prism version 
5. 
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RESULTS 
Patients 
Of 30 patients screened, 18 were randomised (1:1) and 16 completed the 
study. The patients randomised to omalizumab or placebo therapy were well 
matched in terms of distributions of age, sex, body mass index, serum total IgE 
concentrations, smoking history, lung function, asthma symptom scores and 
inhaled corticosteroid dosages (Table I). These dosages were reduced in both 
groups to 400 g/day beclometasone equivalent between 12 and 16 weeks and 
further to 200 g/day between 16 and 20 weeks. In the omalizumab vs. placebo 
treated groups, 7 vs. 8 patients were taking long-acting 2-agonist, 4 vs. 1 were 
taking oral leukotriene receptor antagonist and 2 vs. 2 were taking oral 
theophylline preparations. These medications were all stopped or substituted at 
Time A (Figure 1). One patient randomised to omalizumab and 3 randomised to 
placebo were taking oral prednisolone at dosages of 15 mg/day and 15, 10 and 5 
mg/day respectively which were reduced to 7.5 mg/day and 7.5, 5 and 0 mg/day 
respectively according to the predetermined regimen (see Table E I in the online 
repository section).  
Adverse events and withdrawals 
Two patients randomised to omalizumab therapy withdrew from the 
study prematurely, one following an asthma exacerbation (an expected adverse 
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event) at week 5 and another who elected to withdraw after 16 weeks because of 
subjective deterioration of symptoms not confirmed by spirometry. There were 
no other adverse events. 
Primary outcome measure (FEV1) 
Spirometry was performed at baseline and at Times A and B (Figure I). 
Compared with baseline, the median changes in absolute and % predicted FEV1 
by 20 weeks were positive in the omalizumab treated patients, despite 
substantial reduction of existing anti-asthma treatment, but negative in the 
placebo treated patients (median (SIQR) change 0.325 (0.09,0.66) vs. -0.06 (-
0.14,0.27) litre, p=0.02; 12(3,18.75) vs. -2.0 (-10.5,15.0) % predicted, p=0.009: 
see Figure II).  
Exploratory variables 
As shown in Table I, the median PEF and ACQ scores between baseline 
and Time B improved by what is regarded as a clinically significant degree in 
the patients randomised to omalizumab therapy but not placebo, although the 
differences between the groups did not quite attain statistical significance in 
non-parametric testing. In contrast, ACD and mini-AQLQ scores improved to a 
similar extent in both groups despite reduction of conventional therapy. 
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Markers of airway inflammation 
Median numbers of tryptase
+
 mast cells,  CD20
+
 B cells, CD138
+
 plasma 
cells, total IgE
+
 cells, IgE
+
/tryptase
+
 mast cells, IgE
+
/CD20
+
 B cells and 
IgE
+
/CD138
+
 plasma cells  per unit area of the bronchial biopsy sections just 
prior to commencement of omalizumab or placebo therapy are shown in Table 
II. Percentage changes in these variables between baseline and Time A (Figure 
I) are shown in Table II and Figure III. Omalizumab, compared with placebo 
therapy was associated with significant reduction in the numbers of total IgE
+
 
cells (p<0.001), tryptase
+ 
mast cells (p<0.001) and CD138
+ 
plasma cells 
(p=0.005). Tryptase
+
/IgE
+
 mast cells were also reduced with omalizumab 
treatment but the difference between the groups did not attain statistical 
significance.  No significant difference was observed in changes in mucosal 
CD20
+
 B lymphocyte numbers and BMK-13
+
 eosinophils in the two groups. 
Very few of the B cells and plasma cells showed detectable IgE 
immunoreactivity as expected (Table II), so it was impracticable to evaluate 
changes following omalizumab therapy. 
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DISCUSSION 
In this study, treatment of symptomatic, moderate/severe non-atopic 
asthmatics with omalizumab stabilised and indeed improved lung function in 
the face of substantial reduction of existing therapy which resulted in 
(predictable) deterioration of patients treated with placebo.  All patients treated 
with omalizumab improved their FEV1 under these circumstances within a time 
period used to gauge the outcome of omalizumab therapy in routine clinical 
practise. We contend that this provides proof of concept that omalizumab 
therapy can stabilise asthma and possibly improve lung function, reduce disease 
exacerbations  and spare anti-inflammatory therapy in non-atopic asthma, 
outcomes which are congruent with similar findings in atopic asthmatics such as 
in the landmark INNOVATE study.
7
 Unlike that study, however, the present 
study was neither designed nor powered to detect reductions in exacerbations 
and improvements in quality of life; nevertheless we observed some 
encouraging, if non-significant improvements in some of these outcome 
measures, notably the ACQ score in the patients treated with omalizumab.  This 
perhaps reflects the fact that ACQ is more reflective of short term asthma 
stability, whereas mini–AQLQ, which improved in both the active and placebo 
treated groups, is more influenced by tight asthma monitoring and reassurance 
by the study investigator. Our data are also congruent with a previous, placebo 
controlled 16 week study
31
 designed primarily to examine the effects of 
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omalizumab on the expression of the high-affinity IgE receptor FcRI on blood 
leukocyte subsets in non-atopic asthmatics which also showed an improvement 
in FEV1 in patients treated with omalizumab (ongoing therapy was not altered). 
In defining “non-atopic” for the purposes of this study we are confident 
that we have exceeded the rigour of the definition used in standard clinical 
practice. While it might be argued that it is theoretically impossible to exclude 
the presence of IgE responses to obscure aeroallergens in any individual, and 
while indeed non-conventional “allergens” such as Staphylococcal enterotoxins 
have been implicated in asthma pathogenesis as aforementioned, our argument 
that omalizumab may benefit non-atopic patients as conventionally clinically 
defined remains sound. 
 We also demonstrate for the first time the anti-inflammatory effects of 
omalizumab therapy within the mucosa of the target organ in non-atopic 
asthmatics. Having recently shown that IgE is increased in the bronchial mucosa 
of non-atopic, as well as atopic asthmatics
22
, we here additionally show that 
omalizumab therapy substantially reduced the numbers of cells expressing IgE 
immunoreactivity (most of these cells were likely mast cells). In a subset of 
these patients omalizumab, but not placebo therapy also invariably reduced total 
IgE concentrations in biopsy tissue extracts (data not shown).  We speculate that 
this reflects dissociation of IgE from its receptors following blockade of 
receptor binding, which is followed by down-regulation of  FcRI on target 
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cells such as mast cells and basophils
32-34
: this, as aforementioned, is understood 
to be prima facie the mechanism by which omalizumab exerts its anti-asthma 
effect.  Interestingly, omalizumab therapy also reduced the numbers of 
bronchial mucosal mast cells and plasma cells. We speculate that this is because 
IgE influences mast cell survival and activation to produce cytokines required 
for B cell proliferation, switching to IgE synthesis and plasma cell 
differentiation
35
. Omalizumab does not induce apoptosis of B cells, although it 
has been postulated that it inhibits IgE synthesis
36, 37
, consistent with our data. 
One other study addressing the effects of omalizumab on bronchial mucosal 
inflammation
38
 also showed that treatment of a group of mild, stable atopic 
asthmatics with omalizumab for 16 weeks was associated with reduced numbers 
of bronchial mucosal FcεRI+ cells and IgE+ cells compared with placebo. We 
speculate that, by mechanisms yet to be fully defined, these IgE-dependent 
phenomena can effect destabilisation of asthma in a subset of patients regardless 
of their conventional atopic status. We further speculate that other mediators, 
for example eosinophil products, may be responsible for destabilisation of 
asthma in other subsets of patients. Thus, when defining endotypes of disease in 
order to identify potential responders to new anti-asthma biologicals it might be 
as fruitful to identify endotypes of disease exacerbation as it is to identify 
endotypes of stable disease. 
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It is of interest that the clinical effects of omalizumab in this study were 
observed in the absence of changes in the numbers of bronchial mucosal 
eosinophils.  Like omalizumab, anti-eosinophil biologicals such as 
mepolizumab also stabilise asthma in subsets of patients, but do not necessarily 
normalise lung function. We speculate that there may exist a variety of 
mechanisms for inflammatory destabilisation of asthma, including IgE-
dependent mechanisms, eosinophil-dependent mechanisms and possibly others. 
Thus the only other study of which we are aware addressing the effects of 
omalizumab on bronchial inflammation in mild, atopic asthmatics
38
 found that 
therapy with omalizumab was associated with reductions in bronchial mucosal 
eosinophils, T cells, FcεRI+ cells and IgE+ cells, a small but significant reduction 
in B cells and a trend for reduction in mast cells. These were patients with stable 
disease, in whom lung function (methacholine PC20) was not altered. Clearly 
these questions merit further contemplation and research. 
In summary, the present data support our hypothesis that omalizumab has 
the potential to stabilise asthma and reduce bronchial mucosal inflammation in 
asthma regardless of atopic status as conventionally defined, with the corollary 
that restricting treatment to patients with the “endotype” of atopy may miss 
potential responders. 
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Characteristics & Outcomes Randomisation Baseline Time A Time B 
Age (yr) 
Omalizumab 47 (22, 66)   
Placebo 53.50 (25, 59)   
Sex (M/F) 
Omalizumab 5/3   
Placebo 3/5   
Weight (Kg) 
Omalizumab 84 (55, 133)   
Placebo 87.50 (61, 112)   
Height (cm) 
Omalizumab 172 (155, 178)   
Placebo 166 (152, 177)   
Never smokers (n/8) 
Omalizumab 3   
Placebo 4   
Serum total IgE (IU/ml) 
Omalizumab 75 (8, 264)   
Placebo 49 (2, 284)   
FEV1 (L) 
Omalizumab 2.44 (1.81, 3.43) 0.225 (-0.32, 1.24) 0.325 (0.03, 1.16)* 
Placebo 2.34 (1.16, 3.66) 0.005 (-0.30, 0.45) -0.06 (-0.63, 0.39) 
FEV1 % predicted 
Omalizumab 75 (50, 98) 6 (-13, 36) 12 (1, 29)** 
Placebo 80 (47, 114) -4 (-11, 14) -2 (-23, 15) 
PEF (L/min) 
Omalizumab 364 (233, 480) 10.50 (-3, 55) 17.50 (-34, 104) 
Placebo 308 (174, 455) 8.50 (-41.00, 92.00) 4 (-83, 111) 
ACD score 
Omalizumab 1.75 (0.86, 2.84) 0.00 (-1.15, 0.45) -0.28 (-1.21, 0.65) 
Placebo 1.97 (0.39, 2.80) -0.26 (-1.45, 1.10) -0.24 (-1.52, 2.00) 
ACQ score 
Omalizumab 2.28 (1.43, 3.43) -0.50 (-1.85, 0.72) -0.71 (-1.14, 0.14) 
Placebo 2.42 (0.71, 3.28) -0.35 (-1.00, 0.57) -0.28 (1.71, 1.14) 
AQLQ score 
Omalizumab 4.33 (2.53, 5.27) 0.18 (-1.00, 2.26) 0.46 (-0.40, 2.06) 
Placebo 4.60 (3.73, 5.80) 0.37 (-1.34, 1.87) 0.67 (-1.60, 2.30) 
Inhaled corticosteroid dosage 
(BDP equivalent: μg/day) 
Omalizumab 2000 (800, 4000) 
No change from baseline 
Reduced to 200 μg BDP 
equivalent/day Placebo 1800 (500, 2000) 
 
Table I 
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Table I 
Baseline demographics and clinical characteristics of non-atopic asthmatics 
randomised to omalizumab or placebo therapy and absolute changes from 
Baseline at Times A and B (see Figure 1). All variables are shown as the median 
and range. ACD: Juniper Asthma Control Diary. ACQ: Juniper Asthma Control 
Questionnaire. AQLQ: Juniper mini-Asthma Quality of Life Questionnaire. *p = 
0.02, **p = 0.009 (Mann-Whitney U Test). 
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Table II 
 
Cell Type 
 
Treatment 
Group 
 
Absolute numbers/mm
2
 
at Baseline 
 
% change between 
Baseline and Time A 
 
Mast Cell Omalizumab 7.2 (0.0, 124.8) -80 (-100, -37)*** 
Placebo 29.9 (4.3, 75.6) 22 (-37, 183) 
B Cell Omalizumab 1.5 (0.00, 9.7) 0 (-100, 460)
 
Placebo 2.1 (0.3, 9.4) -11 (-100, 82) 
Plasma Cell Omalizumab 0.0 (0.0, 36.6) -75 (-100, -13)
** 
Placebo 1.7 (0.0, 6.8) 32 (-45, 315) 
IgE
+
 Cell Omalizumab 12.4 (1.2, 175.9) -69 (-83, -28)
*** 
Placebo 16.5 (2.9, 60.9) 40 (-39, 111) 
IgE
+
 Mast cell Omalizumab 9.2 (0.0, 124.5) -56 (-100, 316) 
Placebo 26.2 (4.3, 50.2) 22 (-44, 181) 
IgE
+
  B cell Omalizumab 0.0 (0.0, 0.3) 0 (0, 112) 
Placebo 0.0 (0.0, 0.0) 0 (0, 0) 
IgE
+
 Plasma cell Omalizumab 0.0 (0.0, 6.0) 0  (-100, 0) 
Placebo 0.0 (0, 0.5) 0  (-100, 0) 
Eosinophils Omalizumab 9.03 (2.92, 17.20) -7.80 (-83.72, 37.62) 
Placebo 4.26 (0.31, 21.35) 17.75 (-45.16, 2491.78) 
  
Table II 
Bronchial mucosal inflammatory cells: absolute counts (median, range) per mm
2 
at baseline and % change following treatment with omalizumab/placebo at Time 
A (see Figure I). 
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Figure I 
Clinical trial flow chart outlining interventions. Baseline: Time from screening 
visit to first bronchoscopy and commencement of omalizumab/placebo (Weeks -4 
to 0). Time A: Time span during which the patients had a second bronchoscopy 
(Weeks 12 to 14) after which therapy was reduced. Time B: End of the trial 20 
weeks from the first injection of omalizumab/placebo. 
 
Figure II 
Comparison of effect of treatment with omalizumab and placebo on changes in 
absolute and % predicted FEV1 between Baseline and Times A and B (see Figure 
I for definitions). Bars represent the median and interquartile range; Mann-
Whitney U Test. 
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Figure III  
Effects of omalizumab and placebo treatment on numbers (% change from 
baseline) of bronchial mucosal (A) total IgE
+
 cells; (B) tryptase
+ 
mast cells; (C) 
IgE
+
/tryptase
+
 mast cells; (D) CD138
+
 plasma cells; (E) CD20
+
 B cells. Median 
with interquartile range; Mann-Whitney U Test. (F) Typical immunofluorescence 
images of a bronchial biopsy section stained with anti-CD138 (green), anti-IgE 
(red) and nucleoprotein (blue). 
 
 
 
 
 
 
 
 
 
 
